Wir verwenden Cookies auf unserer Website. Einige von ihnen sind unerlässlich, während andere uns helfen, diese Website und Ihre Erfahrungen zu verbessern.

Notwendig Statistik Marketing
Auswahl bestätigen
Weitere Einstellungen

Hier finden Sie eine Übersicht aller verwendeten Cookies. Sie können ganzen Kategorien Ihre Zustimmung geben oder weitere Informationen anzeigen und bestimmte Cookies auswählen.

Alle auswählen
Auswahl bestätigen
Notwendig Cookies
Wesentliche Cookies ermöglichen grundlegende Funktionen und sind für die ordnungsgemäße Funktion der Website erforderlich.
Statistik Cookies
Statistik-Cookies sammeln anonym Informationen. Diese Informationen helfen uns zu verstehen, wie unsere Besucher unsere Website nutzen.
Marketing Cookies
Marketing-Cookies werden von Werbekunden oder Publishern von Drittanbietern verwendet, um personalisierte Anzeigen zu schalten. Sie tun dies, indem sie Besucher über Websites hinweg verfolgen
    Figure 1
    Acceptance of Real World Data (RWD) for the HTA process among selected European countries (Source: All figures were made by the author/IQVIA Consulting Services).

    Real World Evidence in Health Technology Assessments


    Real World Evidence offers valuable insights for research questions alongside RCTs HTA agencies across Europe base their decisions on RCT data The UK and the Netherlands accept RWE to demonstrate treatment effectiveness in the absence of RCTs In other European countries, RWD is only accepted as supportive evidence In France, RWD can positively influence the HTA decision making RCTs study duration falls short of long-term outcomes, a gap that RWD can close RCTs have often a highly limited external validity RWE is more likely to have a high bias potential but a larger population sample RWD are suitable to analyze patient characteristics and treatment options under real world ... The combination of large data bases with advanced analytic techniques can be very powerful to ... RWE can be generated retrospectively and prospectively. ?Pragmatic trialsʼ are most likely ... Direct-to-patient data collection for HTA submissions RWD use a bigger patient sample size compared to RCT, while providing access to a wide array of ... Anzeigen
    Dirk Eheberg · IQVIA – Munich, Munich
    Dirk Eheberg
    holds a degree in biology from the University of Munich. After a few years working in basic research he started post-graduate studies in epidemiology and public health and completed his studies with a master degree in public health from the University of Munich (MPH). He gained experience in epidemiology, biometrics and working with SAS. Furthermore, he participated in special training programs for decision analytic modelling (decision analysis and Markov models in particular).
    At IQVIA, Dirk Eheberg works as Senior Project Manager and Strategy Lead. Since 2011 he focuses on benefit dossiers, especially on AMNOG dossiers